Interesting late breaker! Telitacicept - recombinant fusion protein targeting BLyS and APRIL for treatment of RA Phase 3
Tweet Content
Interesting late breaker!
Telitacicept - recombinant fusion protein targeting BLyS and APRIL for treatment of RA
Phase 3 study - at wk 24, reached ACR20, ACR50, DAS28-ESR, no radiographic progression
No difference in safety profile compared to placebo
@RheumNow #ACR23 #ACRBest https://t.co/bxWPagGixt
Show on Archive Page
On
Display in Search Results
On
PDQ
Off